OSU-185: first humanized proximal CD30-targeting CAR-T for durable remission in refract. lymphomas
TS-075162 — THE PROBLEM
Despite advances in classical Hodgkin’s Lymphoma (cHL) treatment, significant challenges persist with up to 40% of patients relapsing after first-line therapy and 50% after autologous stem cell transplant (aSCT). Current therapies like brentuximab vedotin and checkpoint inhibitors…
- College: College of Medicine (COM)
- Inventors: Denlinger, Nathan; Chan, Wing
Keung
- Licensing Officer: He, Panqing